Literature DB >> 33577787

Small cell lung cancer enters the era of precision medicine.

Kristopher K Frese1, Kathryn L Simpson1, Caroline Dive2.   

Abstract

In this issue of Cancer Cell, Gay et al. describe a molecular classification of small cell lung cancers and extend prior studies that highlight the potential for personalized treatments. Notably, they identify a new "inflamed" subtype that may emerge following acquired chemoresistance but which may become more susceptible to immunotherapy.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID： 33577787     DOI： 10.1016/j.ccell.2021.02.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  5 in total

1.  Naples Prognostic Score is an Independent Prognostic Factor in Patients with Small Cell Lung Cancer and Nomogram Predictive Model Established.

Authors:  Shuangqing Chen; Shicheng Liu; Siwei Xu; Shumin Cao; Zhaohui Han; Lingxin Kong; Dahu Ren; Guochen Duan
Journal:  J Inflamm Res       Date:  2022-06-28

2.  Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.

Authors:  Bingnan Zhang; C Allison Stewart; Qi Wang; Robert J Cardnell; Pedro Rocha; Junya Fujimoto; Luisa M Solis Soto; Runsheng Wang; Veronica Novegil; Peter Ansell; Lei He; Luisa Fernandez; Adam Jendrisak; Cole Gilbertson; Joseph D Schonhoft; Jiyun Byun; Joshua Jones; Amanda K L Anderson; Ana Aparicio; Hai Tran; Marcelo V Negrao; Jianjun Zhang; Wei-Lien Wang; Ignacio I Wistuba; Jing Wang; Rick Wenstrup; Lauren A Byers; Carl M Gay
Journal:  Br J Cancer       Date:  2022-04-19       Impact factor: 9.075

3.  TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change.

Authors:  Aishwarya Payapilly; Ryan Guilbert; Tine Descamps; Gavin White; Peter Magee; Cong Zhou; Alastair Kerr; Kathryn L Simpson; Fiona Blackhall; Caroline Dive; Angeliki Malliri
Journal:  Cell Rep       Date:  2021-11-09       Impact factor: 9.423

4.  Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report.

Authors:  Zibo Zhang; Yujun Li; Yan Dong; Jia Li; Bin Zhang; Chunxia Zhang; Xiaonan Cui
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 5.738

5.  High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.

Authors:  Shinji Matsui; Tomohiro Haruki; Yuki Oshima; Yoshiteru Kidokoro; Tomohiko Sakabe; Yoshihisa Umekita; Hiroshige Nakamura
Journal:  Thorac Cancer       Date:  2022-03-12       Impact factor: 3.223
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.